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Summary
 
Evidence indicates that cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) may nega-
tively regulate T cell activation, but the basis for the inhibitory effect remains unknown. We
report here that cross-linking of CTLA-4 induces transforming growth factor 
 
b
 
 (TGF-
 
b
 
) pro-
duction by murine CD4
 
1
 
 T cells. CD4
 
1
 
 T helper type 1 (Th1), Th2, and Th0 clones all se-
crete TGF-
 
b
 
 after antibody cross-linking of CTLA-4, indicating that induction of TGF-
 
b
 
 by
CTLA-4 signaling represents a ubiquitous feature of murine CD4
 
1
 
 T cells. Stimulation of the
CD3–T cell antigen receptor complex does not independently induce TGF-
 
b
 
, but is required
for optimal CTLA-4–mediated TGF-
 
b
 
 production. The consequences of cross-linking of
CTLA-4, together with CD3 and CD28, include inhibition of T cell proliferation and inter-
leukin (IL)-2 secretion, as well as suppression of both interferon 
 
g
 
 (Th1) and IL-4 (Th2).
Moreover, addition of anti–TGF-
 
b
 
 partially reverses this T cell suppression. When CTLA-4
was cross-linked in T cell populations from TGF-
 
b
 
1 gene–deleted (TGF-
 
b
 
1
 
2
 
/
 
2
 
) mice, the T
cell responses were only suppressed 38% compared with 95% in wild-type mice. Our data
demonstrate that engagement of CTLA-4 leads to CD4
 
1
 
 T cell production of TGF-
 
b
 
, which,
in part, contributes to the downregulation of T cell activation. CTLA-4, through TGF-
 
b
 
, may
serve as a counterbalance for CD28 costimulation of IL-2 and CD4
 
1
 
 T cell activation.
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R
 
ecent evidence indicates that CTL-associated antigen
4 (CTLA-4),
 
1
 
 a counterreceptor in addition to CD28
for the B7 family of costimulatory molecules, is a negative
regulator of T cell activation (1–4), although this remains
controversial (5). In vitro, antibody cross-linking of
CTLA-4 has been shown to inhibit T cell proliferation and
IL-2 production triggered by anti-CD3 and anti-CD28 an-
tibodies, whereas soluble intact or Fab fragments of anti–
CTLA-4 antibody enhance the proliferative response (2, 6–
8). In vivo, blockade of CTLA-4 with soluble intact or Fab
antibody fragments greatly enhances the T cell response to
peptide antigen (9) or superantigen Staphylococcus entero-
toxin B (10). Furthermore, in vivo administration of anti-
bodies to CTLA-4 promotes tumor rejection (11) and
exacerbates disease in experimental autoimmune enceph-
alomyelitis (12). Direct evidence of a critical regulatory role
for CTLA-4 comes from CTLA-4–deficient (
 
2
 
/
 
2
 
) mice,
which manifest a severe T cell proliferative disorder with
multiorgan lymphocytic infiltration and tissue destruction.
The CTLA-4
 
2
 
/
 
2
 
 animals die by 3–4 wk of age (13, 14).
These results indicate that CTLA-4 is predominantly a
negative regulator of T cell responses. However, the basis
for the inhibitory effects mediated by CTLA-4 signaling
has not yet been well elucidated. One report demonstrated
that CTLA-4 mediates antigen-specific apoptosis of human
T cells (15), whereas others indicate that the primary effect
of CTLA-4 ligation is not the induction of apoptosis, at
least in murine CD4
 
1
 
 T cells (2, 8). In addition, T cells in
CTLA-4
 
2
 
/
 
2
 
 
 
mice exhibit normal levels of apoptosis (16).
TGF-
 
b 
 
elicits diverse cellular responses depending on
cell type, state of differentiation, culture conditions, and
presence of other cytokines (17–19). TGF-
 
b
 
 is a potent in-
hibitor of the T cell–mediated immune response both in
vitro (20, 21) and
 
 
 
in vivo (22–25), although it can also ex-
ert upregulatory effects on T cell proliferative responses
under some conditions (26–28). Interestingly, mice defi-
cient in the TGF-
 
b
 
1 gene also develop massive lympho-
proliferative disorders that lead to organ failure, and die at
the age of 2–3 wk (29–31), similar to the pathogenesis in
CTLA-4
 
2
 
/
 
2
 
 mice. TGF-
 
b
 
 is synthesized by different types
 
1
 
Abbreviations used in this paper:
 
 7-AAD, 7-amino-actinomycin D; B6,
C57BL/6; CTLA-4, CTL-associated antigen 4.
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of cells, including T cells (20, 25, 32), although the molec-
ular basis and pathway(s) involved in T cell production of
TGF-
 
b
 
 are less clear.
Based on the overlapping manifestations in mice defi-
cient in either TGF-
 
b
 
1 or CTLA-4 and their shared im-
munosuppressive actions, we sought in this study to exam-
ine whether TGF-
 
b
 
 is involved in CTLA-4 signaling of T
cells. Our results demonstrate that the cross-linking of
CTLA-4 is an effective inducer of TGF-
 
b
 
 production by
murine CD4
 
1
 
 T cells in vitro. TGF-
 
b
 
 produced by CD4
 
1
 
T cells, in turn, partially suppresses the T cell proliferative
response. These findings establish a previously unrecog-
nized link between CTLA-4–mediated T cell suppression
and TGF-
 
b
 
.
 
Materials and Methods
 
Animals.
 
C57BL/6 (B6) mice were purchased from The Na-
tional Cancer Institute, National Institutes of Health (Bethesda,
MD). TGF-
 
b
 
1
 
2
 
/
 
2
 
 mice were generated by disruption of the
TGF-
 
b
 
1 gene in murine embryonic stem cells by homologous
recombination (30). BALB/c mice were purchased from The
Jackson Laboratory (Bar Harbor, ME). All mice were housed in a
specific pathogen–free rodent facility at the National Institute of
Dental Research.
 
Antibodies and Reagents.
 
Hamster
 
 
 
unconjugated or PE-conju-
gated anti–murine antibodies to CTLA-4 (clone UC10-4F10-
11), CD3 (clone 145-2C11), CD28 (clone 37.51), and purified
IgG isotypic control antibody (clone G235-2356) were purchased
from PharMingen (San Diego, CA). Rat anti–murine FITC-
CD4 (clone CT-CD4), FITC-CD8 (clone CT-CD8a), and the
respective isotypic control mAbs were purchased from Caltag
Laboratories, Inc. (San Francisco, CA). Mouse anti–TGF-
 
b
 
1, 2, 3
mAb was from Genzyme Corp. (Cambridge, MA). Goat anti–
hamster IgG (heavy and light chains) antibody was from Jackson
ImmunoResearch Laboratory (West Grove, PA) and from Pierce
Chemical Co. (Rockford, IL). Crystallized chicken OVA was
purchased from Sigma Chemical Co. (St. Louis, MO). The fol-
lowing reagents were also from PharMingen: purified rat anti–
mouse IL-2 (clone JES6-1A12), IL-4 (clone BVD4-1D11), and
IFN-
 
g
 
 (clone R4-6A2) mAbs; biotinylated anti–mouse IL-2
(clone JES6-5H4), IL-4 (clone BVD6-24G2), and IFN-
 
g
 
 (clone
XMG 1.2) mAbs; and recombinant IL-2, IL-4, and IFN-
 
g
 
.
 
Preparation of CD4
 
1
 
 T Cells.
 
Spleens of B6 and asymptomatic
TGF-
 
b
 
2
 
/
 
2
 
 mice were harvested, and the tissues were gently
minced in HBSS supplemented with 5% fetal bovine serum (FBS;
BioWhittaker, Inc., Walkersville, MD). Cells were then passed
through a cell strainer (Becton Dickinson, Franklin Lakes, NJ),
and red blood cells were lysed with ACK lysing buffer (BioWhit-
taker, Inc.). For CD4
 
1
 
 T cell isolation, spleen cells were first
passed through a nylon wool column and the nonadherent cells
were further purified by using a mouse CD4
 
1
 
 T Cell Column
system (R&D Systems, Minneapolis, MN). By FACS
 
Ò
 
 analysis,
the purity of CD4
 
1
 
 T cells was 
 
.
 
95% with no detectable B cells,
monocytes, or CD8
 
1
 
 T cells. T cell–depleted spleen cells of nor-
mal BALB/c mice, irradiated at 3,000 rad, were used as APCs.
 
CD4
 
1
 
 T Cell Line and Clones.
 
A CD4
 
1
 
 T cell line (CW-
SW-1) and CD4
 
1
 
 T cell clones 2F9 (Th0), 1A11 (Th0), 1G3
(Th2), and 1C5 (Th1) specific for chicken OVA peptide 323–339
were generated from BALB/c mice adoptively transferred with
CD4
 
1
 
 T cells of OVA TCR transgenic mice (33; a gift from Dr.
 
D. Loh, Washington University School of Medicine, St. Louis,
MO) in a tolerance model by intrathymic injection of antigen
(34). All the clones express the specific clonotypic TCR (V
 
b
 
 8.2)
determined by mAb KJ 1–26. Mice were injected intrathymically
with OVA or PBS followed by adoptive transfer of transgenic
CD4
 
1
 
 KJ 1–26
 
1
 
 T cells and immunized 48 h later with OVA and
CFA (Difco Laboratories, Inc., Detroit, MI [34]). On day 5 after
immunization, the draining lymph nodes from these mice were
restimulated in vitro with OVA (100 
 
m
 
g/ml) for 3 d and ex-
panded with recombinant human IL-2 (10 U/ml, Boehringer
Mannheim, Indianapolis, IN) for an additional 3 d. This CD4
 
1
 
 T
cell line (CW-SW-1) specifically proliferated to OVA peptide
323–339 restimulation in the presence of normal BALB/c splenic
APCs. Limiting dilution cloning was carried out by stimulating
the cell line CW-SW-1 (1 or 0.1 cells/well) with irradiated
BALB/c splenic APCs (5 
 
3
 
 10
 
5
 
/well) and OVA (100 
 
m
 
g/ml) in
the presence of rIL-2 (10 U/ml) in 96-well flat-bottomed tissue
culture plates (Costar Corp., Cambridge, MA). 7 d later, rIL-2
(10 U/ml) was added into each well and the cells were cultured
for an additional 10–14 d. CD4
 
1
 
 KJ 1–26
 
1
 
 clones were verified
with the respective mAbs (34) and restimulated with OVA (100
 
m
 
g/ml) for their cytokine profile. Representative Th0, Th2, and
Th1 clones were chosen for this study (Table 1). The T cell
clones were maintained by repetitive stimulation and resting cy-
cles at 1–2-wk intervals by 100 
 
m
 
g/ml of OVA and splenic APCs
of BALB/c mice.
 
Induction of TGF-
 
b
 
.
 
Flat-bottomed 96-well plates (Costar
Corp.) were coated with anti-CD3 (1 
 
m
 
g/ml) only or with anti-
CD28 (10 
 
m
 
g/ml) mAbs in 100 
 
m
 
l PBS for 2 h at 37
 
8
 
C, then
washed extensively and blocked for 30 min at 37
 
8
 
C with com-
plete DMEM containing 10% (vol/vol) heat-inactivated FBS,
2 mM glutamine, 15 mM Hepes, 1% nonessential amino acids,
1 mM sodium pyruvate, penicillin (100 U/ml), streptomycin
(100 
 
m
 
g/ml), and 50 
 
m
 
M 2-ME (all from BioWhittaker, Inc.).
CD4
 
1
 
 T cells (4 
 
3 
 
10
 
5
 
/well) or T cell clone cells (10
 
5
 
/well) were
added in 200 
 
m
 
l of serum-free medium X-Vivo-20 (BioWhit-
taker, Inc.). For cross-linking assays, anti–CTLA-4 or control
hamster IgG antibodies were added at 20 
 
m
 
g/ml or as indicated.
Polyclonal goat anti–hamster antibody was then added at a final
concentration of 20–40 
 
m
 
g/ml. For assaying antibody activity
without cross-linking, anti–CTLA-4 or control hamster IgG anti-
bodies were added at 20 
 
m
 
g/ml without the second goat anti–
hamster antibody. For the induction of TGF-
 
b 
 
with antigen, the
CD4
 
1
 
 T cell line CW-SW-1 was incubated with OVA (100 
 
m
 
g/
ml) and irradiated BALB/c splenic APCs in the presence of anti–
CTLA-4 or control hamster IgG antibodies (40 
 
m
 
g/ml) in X-Vivo-
20 medium. All cultures were incubated at 37
 
8
 
C for 72 h, and the
supernatants were collected and stored at 
 
2
 
70
 
8
 
C before determi-
nation of TGF-
 
b
 
.
 
T Cell Proliferation and Cytokine Induction.
 
The T cell activa-
tion assays were performed as described (7) with modifications
where indicated. CD4
 
1
 
 T cells were incubated with the indicated
antibodies in 200 ml of complete DMEM in round-bottomed 96-
well plates. Anti-CD3 was added at a final concentration of 2 mg/
ml, anti-CD28 at 5 mg/ml, and anti–CTLA-4 or control hamster
IgG at 20 mg/ml. For cross-linking, polyclonal goat anti–hamster
antibody was added at a final concentration of 20 mg/ml. For the
T cell proliferation assay, cells were then cultured at 378C and 5%
CO2 for 72 h and pulsed with 1 mCi of [3H]thymidine (NEN
Research Products, Boston, MA) for the last 8–16 h. Incorpo-
rated radioactivity was counted in a beta counter (Wallac, Gaithers-
burg, MD). For cytokine induction, cell-free supernatants were
collected at 48 h for the determination of IL-2, IFN-g, and IL-41851 Chen et al.
by ELISA. In some experiments, anti–TGF-b1, 2, 3 (20 mg/ml)
and the isotypic control antibodies were added into wells at the
beginning of the culture.
Cytokine ELISAs. Quantitative ELISAs for IL-2, IFN-g, and
IL-4 were performed using paired mAbs specific for the corre-
sponding cytokines according to the manufacturer’s recommen-
dation (PharMingen). A standard curve was generated using
known amounts of purified recombinant murine IL-2, IFN-g,
and IL-4 (PharMingen). TGF-b in the supernatant was deter-
mined by the TGF-b1 EmaxÔ ImmunoAssay System (Promega
Corp., Madison, WI) and by ELISA (25).
Flow Cytometry Analysis. 1–5 3 105 cells were resuspended in
PBS without Ca21 and Mg21 (BioWhittaker, Inc.) containing 1%
BSA (Irvine Scientific, Santa Ana, CA) and 0.1% sodium azide
(Sigma Chemical Co.) (PBS-Az). For the staining of surface anti-
gens, cells were incubated with FITC-conjugated anti–murine
CD4 and PE-conjugated anti–CTLA-4 mAbs or their isotypic
negative control antibodies as indicated on ice for 30 min. After
washing twice with 1 ml of PBS-Az, cells were resuspended in
0.5 ml PBS-Az and analyzed on a FACScanÒ (Becton Dickin-
son). 104 events were routinely collected and analyzed using Lysis
II software (Becton Dickinson Immunocytometry Systems, San
Jose, CA). Both the percentage of positive cells and the mean flu-
orescence intensity of the cells were determined.
Analysis of Cell Viability. For cell viability assays (8), T cells
were cultured exactly as for the proliferation assay. After 24 and
72 h of culture, cell viability was examined by the addition of
one-tenth volume of 0.4% trypan blue, and cell numbers incor-
porating or excluding trypan blue were determined using a
hemocytometer. SDs of the duplicate wells were typically ,10%.
Staining DNA of Apoptotic Cells with 7-AAD. Staining of ap-
optotic cells with 7-amino-actinomycin D (7-AAD) purchased
from Calbiochem Corp. (La Jolla, CA) was performed by the
method described by Schmid et al. (35). In brief, cells were first
stained for surface antigen with FITC-conjugated anti-CD4 mAb
on ice for 30 min. After washing, cells were incubated with 20
mg/ml 7-AAD in PBS-Az for 20 min at 48C protected from
light. Cells were then analyzed by FACScanÒ without further
washing using log scale for FL-3 acquisition to assess 7-AAD
staining. A minimum of 104 events was collected on each sample.
Multiparameter data analysis was performed with Lysis II soft-
ware. CD41 T cells were gated, and 7-AAD staining on FL-3
versus forward scatter channels was displayed. 7-AAD staining is
divided into 7-AADnegative, 7-AADdim, and 7-AADbright, represent-
ing live, early apoptotic, and later apoptotic or dead cells, respec-
tively.
Statistical Analysis. Statistical significance of data was analyzed
by Student’s t test.
Results and Discussion
Cross-linking of CTLA-4 with CD3 and CD28 Inhibits T Cell
Proliferation and Cytokine Production. Stimulation of freshly
purified CD41 T cells from naive B6 mice in the presence of
anti-CD28 enhances cell growth, and as reported (2, 6–8),
cross-linking of CTLA-4 together with the CD3–TCR
complex and CD28 effectively inhibits T cell proliferation
(Fig. 1 A) and IL-2 production (Fig. 1 B). Moreover, we
also show CTLA-4–mediated reduction of IFN-g (Th1)
and IL-4 (Th2) (Fig. 1, C and D). Similar results were ob-
tained using CD41 Th1 and Th2 clones for these studies,
suggesting a common pathway of suppression (Chen, W.,
and S.M. Wahl, unpublished results). Consistent with pre-
vious reports (2, 8), the inhibition of CD41 T cell activa-
tion by engagement of CTLA-4 could not be attributed to
enhanced cell death. No significant increase in apoptosis of
CD41 T cells cross-linked by anti–CTLA-4 mAb was de-
tected either by staining of apoptotic cells with DNA dye
7-ADD for flow cytometry (Fig. 2 A) or by quantifying vi-
able and nonviable cells (Fig. 2 B) at 24–72 h after cell cul-
ture. These data implicate alternative mechanisms of sup-
pressed cell growth.
Cross-linking of CTLA-4 Induces TGF-b Production. To
determine whether TGF-b was involved in the suppression,
CD41 T cells purified from spleens of naive B6 mice were
added to wells containing immobilized anti-CD3 mAb.
More than 90% of these CD41 T cells are CD442, CD692,
CD45RBhi, and CD62L1 and failed to proliferate to immo-
bilized anti-CD3 mAb alone (data not shown), consistent
with their naive/resting status. Although anti-CD3 mAb did
not increase detectable TGF-b in the supernatant compared
with that of cells cultured without anti-CD3 (Fig. 3 A),
more than a fourfold increase in TGF-b levels above the
medium control was induced by the addition of anti–murine
CTLA-4 mAb followed by cross-linking with goat anti–
hamster antibody. This effect was CTLA-4 specific and not
due to the nonspecific binding of immunoglobulin, because
the control hamster antibody had no such effect. Antibody
cross-linking of CD3 and CD28, a regimen for optimal acti-
vation of naive T cells (36), failed to significantly upregulate
Figure 1. Cross-linking of CTLA-4 inhibits cytokine production by
CD41 T cells. CD41 T cells isolated from spleens of B6 mice were cultured
in complete DMEM only (Med) or with the indicated antibodies: anti–
CTLA-4 (20 mg/ml) or control hamster IgG (Ctrl; 20 mg/ml) in the ab-
sence or presence of anti-CD3 (2 mg/ml) and anti-CD28 (5 mg/ml). Goat
anti–hamster IgG (heavy and light chains) antibody was then added to all
the wells at 20 mg/ml. T cell proliferation (A) was expressed as mean 6 SD
of triplicate wells for 3H incorporation (CPM). Secretion of IL-2 (B),
IFN-g (C), and IL-4 (D) by CD41 T cells is shown. Supernatants were col-
lected at 48 h, and the cytokine levels were determined by ELISA. The val-
ues are expressed as mean 6 SD of replicate wells of ELISA plates.1852 CTLA-4 Induces T Cell TGF-b Production
TGF-b production. However, when anti–CTLA-4 mAb
was added to CD41 T cells stimulated with immobilized
anti-CD3 together with anti-CD28, a marked (10-fold) in-
crease in TGF-b occurred (Fig. 3 A). Cross-linking CTLA-4
without CD3–TCR complex failed to increase TGF-b pro-
duction (data not shown).
Two potential mechanisms may account for the TGF-b
production induced by anti–CTLA-4 antibody: stimulation
of CTLA-4 signaling through antibody cross-linking or, al-
ternatively, blockade of CTLA-4 signaling by the antibody.
Since we used a goat anti–hamster antibody for cross-link-
ing, the possibility of CTLA-4 signal transduction was fa-
vored. To further examine this hypothesis, purified CD41
T cells were stimulated with the same regimen as for Fig. 3
A, but without the goat anti–hamster antibody. No TGF-b
was detected in the supernatants of these cell cultures (data
not shown), consistent with a requirement for CTLA-4
cross-linking to signal TGF-b production. CD3, which
does not directly induce TGF-b production, may none-
theless facilitate CTLA-4–induced TGF-b secretion. Al-
though CD3 alone only minimally enhanced CTLA-4 (6;
Fig. 3 B), CD3 plus CD28 stimulation markedly increased
the expression of CTLA-4 on CD41 T cells (Fig. 3 B),
thereby promoting CTLA-4 signaling and TGF-b induction.
Engagement of CTLA-4 in CD41 T Cell Clones Induces
TGF-b. Since it was evident that engagement of CTLA-4
triggered TGF-b production in naive/resting T cells, we
next analyzed whether cross-linking of CTLA-4 provided a
sufficient signal to induce TGF-b production by effector/
memory T cells (37) represented by murine CD41 T cell
clones generated from a tolerance model by intrathymic in-
jection of antigen (Chen, W.J., manuscript in preparation).
Clone 1G3, which expresses clonotypic TCR specific to
chicken OVA peptide 323–339 as determined by mAb KJ
1–26 (33, 34), produces antigen-specific IL-4 but no IFN-g,
and is characterized as a Th2 clone (Table 1). Peak surface
expression of CTLA-4 on clone 1G3 was observed at 48 h
after restimulation with anti-CD3 antibody or OVA in
the presence of syngeneic irradiated BALB/c splenic APCs
(data not shown). Similar to naive CD41 T cells, no de-
tectable TGF-b was found in the supernatants of the clone
cells, whether stimulated with immobilized anti-CD3 alone
or with anti-CD28 antibodies. Surprisingly, cross-linking
of CTLA-4 together with CD3 resulted in the highest
level of TGF-b production (Fig. 4). In contrast to naive/
resting CD41 T cells, cross-linking of CTLA-4 with CD3
Figure 2. Cross-linking of CTLA-4 does not enhance T cell death.
CD41 T cells were activated with the same antibody regimen as described
for Fig. 1 A. (A) After 24 h, cells were stained with FITC–anti-CD4 anti-
body and 7-AAD. CD41 T cells were gated and 7-AAD staining on FL-3
versus forward scatter channels was displayed. (B) Cultured cells were re-
moved and trypan blue was added (reference 8). The numbers of viable
(trypan blue excluding) or dead cells (trypan blue positive) in the control
medium culture were considered as 100%, and the percentage of viable
and dead cells in the treated wells was calculated. The data shown here are
means of duplicate wells, and the variations of duplicate wells are ,10%.
Data in the figure are cells after 72 h of culture. Similar results were ob-
tained after 24 and 48 h of cell culture (not shown).
Figure 3. CTLA-4 expression and
cross-linking to induce TGF-b. (A) Puri-
fied naive CD41 T cells were added to
96-well plates coated with anti–murine
CD3 (1 mg/ml) without or with anti-
CD28 (10 mg/ml). Anti–murine CTLA-4
or its isotypic control hamster IgG was
added into the cultures at 20 mg/ml fol-
lowed by goat anti–hamster IgG antibody
(20 mg/ml). Cells were incubated in se-
rum-free medium for 72 h. TGF-b in the
supernatants was determined by ELISA.
The data are expressed as mean 6 SD of
replicate wells (absence of SD bars indi-
cates ,10% of mean). The data shown
here are representative of three experi-
ments. (B) CD41 T cells were stimulated with immobilized anti-CD3 (1 mg/ml) without or with anti-CD28 (10 mg/ml) antibodies as indicated for 48–56 h.
Cells were then stained with FITC–anti-murine CD4 and PE-conjugated anti-CTLA-4 mAbs. Cells were analyzed on a FACScanÒ with Lysis II soft-
ware. Data shown are CTLA-4 fluorescence as expressed in FL-2 histograms. Fluorescence histograms of negative control PE–hamster IgG antibody, as
well as CTLA-4 expression on freshly isolated CD41 T cells (data not shown), are not different from medium-treated CD41 T cells.1853 Chen et al.
plus CD28 did not further augment TGF-b levels com-
pared with supernatants of the clone cells stimulated with
anti–CTLA-4 and anti-CD3 (Fig. 4 A). Similar results
were obtained when the OVA-specific CD41 Th1 clone
1C5 and Th0 clone 2F9 were cultured with the same regi-
men of antibody stimulation (Fig. 4 A). These results indi-
cate that the induction of TGF-b by CTLA-4 signaling is
probably a ubiquitous feature of murine CD41 T cells. A
clear dose dependence of CTLA-4 antibody was found in
the induction of TGF-b by CD41 T cells. With increasing
concentrations of anti–CTLA-4 antibody, TGF-b produc-
tion was proportionally enhanced (Fig. 4 B).
The discrepancy in the requirement for CD28 for
CTLA-4–induced TGF-b production between naive and
effector (clone) CD41 T cells is of interest. It is possible
that the requirement for costimulator CD28 during restim-
ulation of CD41 effector T cells is greatly diminished (38)
compared with naive CD41 T cells (37). Optimal activa-
tion and, therefore, CTLA-4 expression of CD41 naive T
cells require the coengagement of CD3–TCR complex
and CD28 (2, 6; Fig. 3 B), whereas signaling of effector
cells via CD3–TCR with the respective mAb appears inde-
pendently sufficient to activate CD41 T cell clones (37)
and CTLA-4 expression. Costimulation of CD28 failed to
further increase CTLA-4 expression (data not shown).
Cross-linking of CTLA-4 Upregulates TGF-b Secretion in
CD41 T Cells Stimulated by Peptide Antigen. In the next
series of experiments, we examined the effects of anti–
CTLA-4 cross-linking on TGF-b production by T cells
stimulated with antigen in the presence of syngeneic APCs.
The CD41 T cell line CW-SM-1, specific to OVA peptide
323–339, was restimulated with OVA and irradiated
splenic APCs in the presence of anti–CTLA-4 or isotypic
hamster IgG control antibodies. Under these conditions,
CTLA-4 can be cross-linked by anti–CTLA-4 via its Fc
fragment binding to Fc receptors on APCs (2, 6), which
markedly enhanced antigen-specific TGF-b production
(Fig. 5). It was noted that low but detectable TGF-b was
also found in the supernatants of cells stimulated with anti-
Table 1. Cytokine Profile of CD41 T Cell Clones
Clone
Phenotype
(CD41, KJ 1-261) IFN-g* IL-4* Th
% pg/ml pg/ml
1G3 100 ,15 307 Th2
1C5 100 574 ,5 Th1
2F9 100 1,843 279 Th0
1A11 100 101 186 Th0
*Cells were stimulated with OVA (100 mg/ml) in the presence of
splenic APCs from BALB/c mice. Cytokine levels in 48-h supernatants
were determined by ELISA.
Figure 4. CTLA-4 dose-dependent induction of TGF-b. (A) CD41 Th2, Th1, and Th0 cell clones specific for OVA peptide 323–339 were restimu-
lated with the antibody regimen as described for Fig. 3 A. TGF-b was determined by ELISA. The data are expressed as mean 6 SD of duplicate cultures.
(B) The CD41 T cell clone 1A11 (Th0, Table 1) was stimulated with immobilized anti-CD3 (1 mg/ml) and different concentrations of anti–CTLA-4 or
isotypic hamster IgG antibodies for 72 h. Supernatant TGF-b was determined in duplicate by ELISA, and the variations of the means are ,10%.
Figure 5. Engagement of CTLA-4 with antibody and stimulation of
TCR by antigenic peptide upregulates TGF-b secretion. CD41 T cell
line CW-SW-1 specific for OVA peptide 323–339 was restimulated with
OVA antigen (100 mg/ml) in the presence of normal BALB/c splenic
APCs in X-Vivo-20. Anti–CTLA-4 (40 mg/ml) or the isotypic control
hamster IgG (Ham-IgG Ctrl; 40 mg/ml) was added into the indicated cul-
ture wells. The supernatants were collected 72 h later and TGF-b was de-
termined by ELISA.1854 CTLA-4 Induces T Cell TGF-b Production
gen and APCs in the absence of anti–CTLA-4 mAb. It was
unlikely that this TGF-b induced by OVA stimulation was
derived from the irradiated APCs in the culture, since no
TGF-b was detected in the cultures of the T cell line and
APCs without the antigen (Fig. 5). Rather, the TGF-b in-
duced by antigen and APCs can more likely be attributed
to the engagement of CTLA-4 by its natural B7 family
ligands on APCs. However, whether and how these B7-1
(CD80), B7-2 (CD86), and/or B7x (3, 5, 15, 36) mole-
cules contribute to TGF-b production by engaging CTLA-4
signaling remain to be determined. Consistent with our
previous data, addition of anti-CD28 mAb in this system
failed to upregulate OVA-specific TGF-b production (data
not shown). Importantly, these results demonstrate that
cross-linking/engagement of CTLA-4 is able to induce
TGF-b production by CD41 T cells stimulated with pep-
tide antigen presented by APCs, as well as with specific
antibody.
Inhibition of CD41 T Cell Activation by Engagement of
CTLA-4 Is Associated with Increased TGF-b. A critical ques-
tion that arises is whether the suppression of T cell activa-
tion caused by CTLA-4 engagement can, in fact, be attrib-
uted to the emergence of TGF-b. Since TGF-b is a potent
inhibitor for T cell–mediated responses (19, 21, 39) and
cross-linking CTLA-4 induces substantial levels of TGF-b
(Fig. 3 A), it is reasonable to envision that TGF-b may play
a part in suppression of CD41 T cell activation initiated by
CTLA-4 cross-linking. Consistent with the kinetics of
TGF-b production in CD41 T cells (20), we have ob-
served that suppression of CD41 T cell activation due to
cross-linking of CTLA-4 is delayed. Similar kinetics of sup-
pression have been reported using the same CTLA-4 cross-
linking antibody (2), although a different mAb induces an
earlier response (24 h; reference 8). Whether this difference
represents recognition of different epitopes by the antibod-
ies is unclear, but TGF-b appears to contribute to the sup-
pression. First, anti–TGF-b neutralizing mAb included in
the CD41 T cell proliferation assay, but not the isotypic
control IgG, partially restored CD41 T cell proliferation
in a dose-dependent fashion. The suppression caused by
CTLA-4 engagement (12,287 cpm) was partially restored
(nearly threefold) by the inclusion of anti–TGF-b antibody
(32,587 cpm), although it remained lower than the control
proliferative response (anti-CD3 1 anti-CD28 1 hamster
IgG: 118,229 cpm; Fig. 6). Second, we compared CD41
T cells from TGF-b12/2 mice with their wild-type
TGF-b11/1 littermates for activation with anti-CD3 and
anti-CD28 mAbs together with CTLA-4 cross-linking. As
shown (Fig. 1 A), CTLA-4 engagement profoundly inhib-
ited T cell proliferation (90–96% suppression) in the wild-
type T cells, in contrast to T cells from TGF-b12/2 mice
(Fig. 7). Although TGF-b12/2 T cells are less proliferative
in vitro than wild-type T cells (31) using optimal condi-
tions of anti-CD3 and anti-CD28 antibodies for the wild-
type and making comparisons difficult, we adjusted the
anti-CD3 and anti-CD28 concentrations to increase pro-
liferation of the TGF-b12/2 CD41 T cells (Fig. 7). Simi-
lar to wild-type CD41 T cells, anti-CD3 and anti-CD28
mAbs induced significant expression of CTLA-4 on the
TGF-b12/2 T cells after 48 h of culture (.50% of CD41
T cells become positive; Fig. 7 A). However, CTLA-4
cross-linking only suppressed the TGF-b12/2 T cell pro-
liferation by 30–40% (Fig. 7 B), supporting the hypothesis
that TGF-b1 contributes to CTLA-4–mediated suppres-
sion of T cell activation. Since engagement of CTLA-4 in
TGF-b12/2 CD41 T cells still results in some degree of
suppression of T cell proliferation, other inhibitory mole-
cules may also be associated with CTLA-4 signaling. Col-
lectively, these data indicate that stimulation of CTLA-4
inhibits CD41 T cell activation, at least in part, by induc-
ing TGF-b production, which then downregulates their
immune responsiveness.
Our results that cross-linking of anti–CTLA-4 mAb in-
duces TGF-b production, which then reduces T cell acti-
vation, offer an explanation for the mechanisms whereby
the CTLA-4 molecule functions as a negative regulator of
T cell responses in vitro (2, 6–8). This finding also has im-
plications in our understanding of the function of CTLA-4
in T cell immune responses in vivo.
Despite the apparent unrelatedness of the two molecules,
emerging evidence has begun to link TGF-b and CTLA-4.
Genes for both CTLA-4 (2, 3) and TGF-b (for reviews,
see references 39 and 40) are highly conserved among
mouse, rat, and human species. Engagement of CTLA-4
results in profound inhibition of T cell activation triggered
by TCR stimulation, including suppression of T cell cycle
Figure 6. TGF-b is associated with inhibition of CD41 T cell activa-
tion by CTLA-4 cross-linking. CD41 T cells isolated from B6 spleens
were cultured with anti-CD3 (2 mg/ml), anti-CD28 (5 mg/ml), and anti–
CTLA-4 (20 mg/ml) followed by goat anti–hamster IgG (Ham-IgG; 20
mg/ml). Anti–TGF-b mAb or isotypic control antibody (mouse IgG1)
was included from the beginning of the culture at the indicated concen-
trations. Cells were cultured for 72 h. Data are expressed as mean cpm 6
SD of triplicate wells for [3H]thymidine incorporation. Data not shown in
the figure are cpm of T cells incubated with medium alone (176 6 26).
The experiments were repeated three times with similar results.1855 Chen et al.
(2, 8), decreased IL-2 production, and reduction of both
Th1 and Th2 cytokines (Fig. 1). TGF-b has a similar pro-
file of activities (19, 20, 41). Neither engagement of
CTLA-4 (2, 8, 16) nor inclusion of TGF-b (37) induces
apoptosis in murine CD41 T cell cultures. Recombinant
IL-2 is able to reverse the inhibition induced either by
CTLA-4 cross-linking (2) or by exogenous TGF-b (20;
Chen, W., and S.M. Wahl, manuscript in preparation).
Most importantly, disruption of TGF-b1 (29, 30) or
CTLA-4 (13, 14) genes in mice leads to massive inflamma-
tion, multiorgan lymphocyte infiltration, and spontaneous
T cell activation. Both genotypes are associated with death
at the age of 2–4 wk. Now our data further strengthen this
link by demonstrating that CTLA-4 acts as a negative regu-
lator by inducing TGF-b and possibly other inhibitory
molecules in T cells.
In vivo, the pathways whereby anti–CTLA-4 antibody
functions remain to be determined, although either block-
ade or stimulation of CTLA-4 by the injected antibodies
may occur. Blockade of CTLA-4 signaling by the anti-
body may lead to a loss of TGF-b production by T cells.
Since TGF-b contributes to immune tolerance, suppres-
sion of autoimmune diseases in animal models (23–25, 42–
44), and inhibition of antitumor immunity of T cells infil-
trating into tumors (45–48), loss of TGF-b production and
removal of this potent inhibitor of T cells could release a
“brake” on T cell activation. Consequently, augmentation
of the T cell antitumor immune response (11) and exacer-
bation of autoimmune diseases such as experimental auto-
immune encephalomyelitis due to increased IL-2 and IFN-g
production may occur (3, 12). On the other hand, if anti–
CTLA-4 antibody given in vivo cross-links CTLA-4 on T
cells via its Fc fragment on FcR1 cells, T cells might com-
mence production of TGF-b to effect immune suppres-
sion, tolerance (49), and inhibition of tumor growth (50–
52). Thus, based on our in vitro data, it is now possible
to reevaluate the in vivo impact of CTLA-4 antibodies
on TGF-b production and their cooperative roles in me-
diating antitumor responses, immunoregulation, and toler-
ance.
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